Bristol-Myers Squibb Company (BMY) DCF Valuation

Bristol-Myers Squibb Company (BMY) DCF Valuation
  • ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • ✓ Aucune Expertise N'Est Requise; Facile À Suivre

Bristol-Myers Squibb Company (BMY) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Gain insights into your Bristol-Myers Squibb Company (BMY) valuation analysis using our sophisticated DCF Calculator! Fully equipped with real (BMY) data, this Excel template enables you to adjust forecasts and assumptions to accurately determine the intrinsic value of Bristol-Myers Squibb Company.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 26,145.0 42,518.0 46,385.0 46,159.0 45,006.0 48,831.1 52,981.3 57,484.2 62,369.8 67,670.7
Revenue Growth, % 0 62.62 9.09 -0.48723 -2.5 8.5 8.5 8.5 8.5 8.5
EBITDA 7,440.0 5,035.0 20,191.0 19,232.0 19,366.0 16,458.3 17,857.1 19,374.7 21,021.4 22,808.0
EBITDA, % 28.46 11.84 43.53 41.66 43.03 33.7 33.7 33.7 33.7 33.7
Depreciation 1,809.0 10,486.0 10,759.0 10,287.0 9,811.0 9,655.1 10,475.7 11,366.0 12,332.0 13,380.1
Depreciation, % 6.92 24.66 23.19 22.29 21.8 19.77 19.77 19.77 19.77 19.77
EBIT 5,631.0 -5,451.0 9,432.0 8,945.0 9,555.0 6,803.2 7,381.4 8,008.8 8,689.4 9,427.9
EBIT, % 21.54 -12.82 20.33 19.38 21.23 13.93 13.93 13.93 13.93 13.93
Total Cash 12,346.0 14,546.0 13,979.0 9,123.0 12,280.0 15,491.1 16,807.7 18,236.2 19,786.1 21,467.7
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 7,685.0 8,501.0 12,516.0 13,937.0 15,264.0
Account Receivables, % 29.39 19.99 26.98 30.19 33.92
Inventories 4,293.0 2,074.0 2,095.0 2,339.0 2,662.0 3,593.6 3,899.0 4,230.4 4,590.0 4,980.1
Inventories, % 16.42 4.88 4.52 5.07 5.91 7.36 7.36 7.36 7.36 7.36
Accounts Payable 2,445.0 2,713.0 2,949.0 3,040.0 3,259.0 3,507.8 3,805.9 4,129.4 4,480.3 4,861.1
Accounts Payable, % 9.35 6.38 6.36 6.59 7.24 7.18 7.18 7.18 7.18 7.18
Capital Expenditure -836.0 -753.0 -973.0 -1,118.0 -1,209.0 -1,189.0 -1,290.1 -1,399.7 -1,518.7 -1,647.7
Capital Expenditure, % -3.2 -1.77 -2.1 -2.42 -2.69 -2.43 -2.43 -2.43 -2.43 -2.43
Tax Rate, % 4.92 4.92 4.92 4.92 4.92 4.92 4.92 4.92 4.92 4.92
EBITAT 3,892.5 -7,136.0 8,146.1 7,337.6 9,085.2 5,886.2 6,386.5 6,929.3 7,518.2 8,157.2
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -4,667.5 4,268.0 14,132.1 14,932.6 16,256.2 15,213.9 14,398.8 15,622.5 16,950.3 18,390.9
WACC, % 5.64 6 5.84 5.79 5.94 5.84 5.84 5.84 5.84 5.84
PV UFCF
SUM PV UFCF 67,754.6
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 18,759
Terminal Value 488,209
Present Terminal Value 367,543
Enterprise Value 435,298
Net Debt 30,000
Equity Value 405,298
Diluted Shares Outstanding, MM 2,078
Equity Value Per Share 195.04

What You Will Get

  • Pre-Filled Financial Model: Bristol-Myers Squibb’s actual data enables precise DCF valuation.
  • Full Forecast Control: Adjust revenue growth, margins, WACC, and other key drivers.
  • Instant Calculations: Automatic updates ensure you see results as you make changes.
  • Investor-Ready Template: A refined Excel file designed for professional-grade valuation.
  • Customizable and Reusable: Tailored for flexibility, allowing repeated use for detailed forecasts.

Key Features

  • Accurate Financial Data: Gain access to reliable pre-loaded historical figures and future forecasts for Bristol-Myers Squibb Company (BMY).
  • Adjustable Forecast Parameters: Modify highlighted cells such as WACC, growth rates, and profit margins to tailor your analysis.
  • Real-Time Calculations: Enjoy automatic updates for DCF, Net Present Value (NPV), and cash flow evaluations.
  • User-Friendly Dashboard: Utilize clear charts and summaries to effectively visualize your valuation insights.
  • Designed for All Skill Levels: A straightforward, intuitive layout catering to investors, CFOs, and consultants alike.

How It Works

  • Download: Obtain the pre-prepared Excel file featuring Bristol-Myers Squibb’s financial data.
  • Customize: Modify projections, including revenue growth, EBITDA %, and WACC.
  • Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
  • Test Scenarios: Develop various forecasts and analyze results immediately.
  • Make Decisions: Leverage the valuation outcomes to inform your investment approach.

Why Choose This Calculator for Bristol-Myers Squibb (BMY)?

  • Designed for Industry Experts: A sophisticated tool tailored for analysts, financial officers, and consultants.
  • Accurate Financial Data: Historical and projected financials for Bristol-Myers Squibb preloaded for precision.
  • Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
  • Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
  • User-Friendly Interface: Step-by-step guidance ensures a smooth experience.

Who Should Use This Product?

  • Investors: Evaluate Bristol-Myers Squibb's valuation before making stock trades.
  • CFOs and Financial Analysts: Optimize valuation methodologies and assess forecasts.
  • Startup Founders: Discover how leading pharmaceutical companies like Bristol-Myers Squibb are appraised.
  • Consultants: Provide comprehensive valuation analyses for your clients.
  • Students and Educators: Utilize real-time data to practice and teach valuation strategies.

What the Template Contains

  • Historical Data: Includes Bristol-Myers Squibb’s past financials and baseline forecasts.
  • DCF and Levered DCF Models: Detailed templates to calculate Bristol-Myers Squibb’s intrinsic value.
  • WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
  • Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
  • Quarterly and Annual Statements: A complete breakdown of Bristol-Myers Squibb’s financials.
  • Interactive Dashboard: Visualize valuation results and projections dynamically.

No products were found matching.